Cancer Cell Research (Online ISSN: 2161-2609)
 |
Current Issue
Vol.1 No.3
Article: Impact of Surgery Extent on Survival and Recurrence Rate of Stage ⅠEndometrial Adenocarcinoma
by Wenping Hou, Zhumei Cui
Cancer Cell Research 2014 1(3) 65-69; published online 25 April 2014
Abstract: The total number of 349 patients of stage Ⅰ endometrial adenocarcinoma treated with surgery in Qingdao University Affiliated Hospital from January 2007 to December 2012 were analyzed retrospectively. They were divided into two groups: Group A (extrafascial hysterectomy plus bilateral salpingo- oophorectomy) and Group B (extrafascial hysterectomy or entensive hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymph node dissection), and then the survival and recurrence conditions were explored. The five-year survival rates of the two groups were 98.35% and 97.7% respectively (P>0.05). Among the 349 patients, there were 6 patients who recurred within 2 to 38months. The recurrence rates of Group A and Group B were 1.67% (3/178) and 1.75% (3/171) respectively (P>0.1). In this study, there were 129 stageⅠA moderately differentiated patients. None of the 17 patients who adopted adjuvant treatments relapsed; 4 of 112 patients without post-operative treatment recurred. There was no significant difference of recurrence rates (P>0.05). This study showed that to stage Ⅰendometrial adenocarcinoma patients, lymphadenectomy will not promote the survival rate and lower recurrence rate, however, to patients with risk factors it is still necessary to explore lymphadenectomy and adjuvant therapy. Perhaps adjuvant therapy can benefit the stage ⅠA moderately differentiated patients.
Open Access Download (free) PDF
Article: Expression of IGF-IR in Breast Cancer tissue before and after Neoadjuvant Chemotherapy
by Ximing Shen, Dongxia Wu, Xinxin He, Gengbiao Chen, Yunjie Zeng
Cancer Cell Research 2014 1(3) 70-75; published online 19 May 2014
Abstract: Neoadjuvant chemotherapy (NAC) is a common therapeutic schedule in treatment of breast cancer. In order to discover the mechanism of IGF-IR in breast cancer tissue and its influence on cell proliferation and CAM angiogenesis and NAC effect. 160 breast cancer patients in II and III period were selected and tested the expression of IGF-IR. All the patients were diagnosed according to specimen taken with needle biopsy and treated with NAC (Duoxitasai, epirubicin and cyclophosphamide) for 2 months, had mastectomy and tested expression of IGF-IR. The results showed that positive expression rate of IGF-IR in breast cancer patients were73.125% and the expression of IGF-IR is closely related with the periods of tumor and Axillary node metastases (P=0.01) but not related with tumor size (P=0.21). After treatment, IGF-IR in 65 patients had changed from high-expression to low expression (P=0.001) and negative conversion rate was 55.56%. Total effective rate of patients whose IGF-IR is positively expressed was 84.62%, which is obviously lower than that of patients with IGF-IR negatively expressed (P=0.035). IGF-IR before treatment is closely related to VEGF, MVD and ki-67 (P=0.001). NAC can partly inhibit expression of IGF-IR to inhibit tumor growth and treatment with IGF-IR can effectively inhibit proliferation of breast cancer cells and CAM angiogenesis ability.
Open Access Download (free) PDF
Article: Role of Toll-like receptors in nonresolving inflammation-related cancer
by Chun-lin Ou, Zhen-qiang Sun, Xiao-ling Li
Cancer Cell Research 2014 1(3) 76-82; published online 19 May 2014
Abstract: To some degree, the relationship between nonresolving inflammation and cancer has been confirmed. Inflammatory cells and cytokines infiltrates tumor tissue in tumor microenvironment. Toll-like receptors, as an important pattern recognition receptors(PRRs) are closely associated with tumor microenvironment formation and play an important role in regulating tumorigenesis. Thus, deeper investigation into molecular effect mechanism of Toll-like receptors is highly worthwhile for tumor prevention, early diagnosis and treatment.
Open Access Download (free) PDF
Review: Research on Golgi Protein 73 and Its Corpora Heterogenium
by Chengcheng Li, Meng Liu, Hongzong Si, Lianhua Cui
Cancer Cell Research 2014 1(3) 83-86; published online 19 September 2014
Abstract: Hepatocellular carcinoma (HCC) is one of the most frequent malignancies, so early diagnosis is crucial to HCC. In recent years, with the rapid development of proteomics and glycomics, new various serum markers related hepatocellular carcinoma were found in succession. Although it is reported that golgi protein 73 (GP73) and its corpora heterogenium (Fucosylated gp73, Fuc-gp73) can be the serum marker used to the diagnosis of HCC, there is certain limitation in current study. Therefore, our study combined with the current domestic and foreign literature, to conduct a review about research progress of GP73 and Fuc - GP73.
Open Access Download (free) PDF